about
Menopause, obesity and inflammation: interactive risk factors for Alzheimer's diseaseInteractions of metals and Apolipoprotein E in Alzheimer's diseaseAlzheimer mechanisms and therapeutic strategiesLRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowthThe Alzheimer's amyloid β-peptide (Aβ) binds a specific DNA Aβ-interacting domain (AβID) in the APP, BACE1, and APOE promoters in a sequence-specific manner: characterizing a new regulatory motifGenetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathwaysTau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseNeurodegeneration and microtubule dynamics: death by a thousand cutsMetabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and TreatmentResearch progress on flavonoids isolated from traditional Chinese medicine in treatment of Alzheimer's diseaseThe 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotypeEffect of the inhaled anesthetics isoflurane, sevoflurane and desflurane on the neuropathogenesis of Alzheimer's disease (review)Neuroinflammation in Alzheimer's diseaseGenetic markers in biological fluids for aging-related major neurocognitive disorderNeuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation3D culture models of Alzheimer's disease: a road map to a "cure-in-a-dish"Fisetin stimulates autophagic degradation of phosphorylated tau via the activation of TFEB and Nrf2 transcription factorsFLZ alleviates the memory deficits in transgenic mouse model of Alzheimer's disease via decreasing beta-amyloid production and tau hyperphosphorylationSynthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholAftins increase amyloid-β42, lower amyloid-β38, and do not alter amyloid-β40 extracellular production in vitro: toward a chemical model of Alzheimer's disease?Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer diseaseMitochondria are related to synaptic pathology in Alzheimer's disease.Folic Acid Reduces Tau Phosphorylation by Regulating PP2A Methylation in Streptozotocin-Induced Diabetic Mice.FLAP pharmacological blockade modulates metabolism of endogenous tau in vivo .Regulation of age-related structural integrity in neurons by protein with tau-like repeats (PTL-1) is cell autonomous.PTL-1 regulates neuronal integrity and lifespan in C. elegans.Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L miceParaquat, but not maneb, induces synucleinopathy and tauopathy in striata of mice through inhibition of proteasomal and autophagic pathwaysIs there a risk of prion-like disease transmission by Alzheimer- or Parkinson-associated protein particles?Sevoflurane induces tau phosphorylation and glycogen synthase kinase 3β activation in young miceInfantile postnatal exposure to lead (Pb) enhances tau expression in the cerebral cortex of aged mice: relevance to AD.Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity.Model Hirano bodies protect against tau-independent and tau-dependent cell death initiated by the amyloid precursor protein intracellular domain.Tissue-based Alzheimer gene expression markers-comparison of multiple machine learning approaches and investigation of redundancy in small biomarker setsDrosophila melanogaster as a model organism for Alzheimer's disease.Enhanced taupathy and AD-like pathology in aged primate brains decades after infantile exposure to lead (Pb).Resveratrol as a therapeutic agent for Alzheimer's disease.Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases.Extracellular α-synuclein leads to microtubule destabilization via GSK-3β-dependent Tau phosphorylation in PC12 cellsPET Imaging of Tau Pathology in Alzheimer's Disease and Tauopathies.
P2860
Q21131065-ED838E0E-512C-4237-85B8-07328FEEB62EQ21131068-BBBD6D93-BCEE-4282-9513-CD732E5A3A2AQ22252311-A7ACBA36-A383-41BF-A73C-D2E3203FC10AQ24304347-9058F2C4-DA9E-4E4A-8E16-FF23A125DBB0Q24600203-309F4078-E4ED-4932-8E75-547D1A19921EQ24629875-F491E8FB-EC74-4114-AD76-F29F3A6727E7Q26739412-C3D816A8-0267-4F94-B31A-1E99D3AED474Q26781649-F332ACE7-F072-4E3E-B365-393F30B851C2Q26799893-EEFFD8BA-07DB-414B-AE8C-80D2266916ABQ26998487-605118FC-D658-48BA-83CE-BC75CD268D54Q26999358-D1D75AB1-3263-40F9-8432-56F5C9F7CBCBQ27001244-99467FA5-FD7C-4495-9398-42F9FBFE5CCAQ27004226-8535D337-ADDA-4739-AEE9-B21265ADE351Q27027348-8794DED4-2BE0-426C-8387-1FD809D8F00CQ27499804-4B63CD90-660B-4A14-B2C3-69F81698DDCFQ28078900-B8A37313-0378-4D5D-94D6-286CB9AFA4E9Q28393031-BD482853-0CFE-4A6A-B5E9-626A059A9BADQ28534810-93A23D74-3E4F-4914-8229-E770B1D03C9EQ28818062-4F24FA52-15AE-4FB9-A683-684362647B36Q28828789-97919019-4B27-4D87-8848-F971FF6ADEFEQ30412891-6908798A-6830-4687-9039-F289CA17D775Q30474134-313A67DD-1D04-4545-8833-1840FC734770Q33624894-7F48D8CB-C8E5-4559-84E8-49A1174FFB41Q33647503-67EF9CE6-B792-4BF2-82FD-4938CA121AE1Q33713496-70A04787-25DE-4AD6-B4C7-C212ED3D1557Q33798637-F0315DD0-655D-4D66-8531-20F910A1D81DQ33865294-BA8E88B1-D393-4180-A831-3AF768F460E8Q34146349-58D987DF-1045-4B32-9422-AF950A5DA095Q34157427-B687D619-5711-4FD3-B601-1626F7054F39Q34195717-6845AF8F-7D78-4651-92F2-73ED9F6A451EQ34243873-1CDCE118-C2C8-43BD-B529-728449DA04C7Q34329880-A6883E00-BCB4-43C1-BAA1-8A1C881AC056Q34427848-3F147D84-CC04-4164-A4DB-3BA447225AECQ34445687-D55C8469-0A36-4EA5-BCC7-28C304E54914Q34464181-A98E74DC-8824-479E-8BE9-F6B0B35CEADDQ34655631-DEDF218C-74CD-46BB-AD4B-8BEAF1145744Q34667472-B9B42A6A-909A-4281-98C3-C124BEA6DD84Q35000764-8DF9ED6D-64AB-4E77-8C48-370B8FFEAA34Q35144986-DA506D28-AD6C-4D6B-B05D-6820D9636DE8Q35158227-93A87235-40DA-4341-8994-7391A31D9762
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Tau in Alzheimer disease and related tauopathies.
@ast
Tau in Alzheimer disease and related tauopathies.
@en
Tau in Alzheimer disease and related tauopathies.
@nl
type
label
Tau in Alzheimer disease and related tauopathies.
@ast
Tau in Alzheimer disease and related tauopathies.
@en
Tau in Alzheimer disease and related tauopathies.
@nl
prefLabel
Tau in Alzheimer disease and related tauopathies.
@ast
Tau in Alzheimer disease and related tauopathies.
@en
Tau in Alzheimer disease and related tauopathies.
@nl
P2093
P2860
P1476
Tau in Alzheimer disease and related tauopathies.
@en
P2093
P2860
P304
P356
10.2174/156720510793611592
P577
2010-12-01T00:00:00Z